Curis, Inc. (CRIS)
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
$35.04M
Mr. James E. Dentzer
60.00
Lexington, MA
Aug 01, 2000
-0.72
$-8.17
0.52
1.78
-468.85%
-0.75
-4.64
-51.73
3.63
1.78
-94.50%
-328.39%
Similar stocks (11)
Day One Biopharmaceuticals, Inc.
DAWN
Terns Pharmaceuticals, Inc.
TERN
Inozyme Pharma, Inc.
INZY
Corvus Pharmaceuticals, Inc.
CRVS
X4 Pharmaceuticals, Inc.
XFOR
PDS Biotechnology Corporation
PDSB
Leap Therapeutics, Inc.
LPTX
Aileron Therapeutics, Inc.
ALRN
Pieris Pharmaceuticals, Inc.
PIRS
Artelo Biosciences, Inc.
ARTL
Histogen Inc.
HSTO
ETF Exposure (12)
iShares Micro-Cap ETF
IWC
0.00806%
Dimensional U.S. Core Equity 2 ETF
DFAC
1.727e-5%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (11)
Day One Biopharmaceuticals, Inc.
DAWN
Terns Pharmaceuticals, Inc.
TERN
Inozyme Pharma, Inc.
INZY
Corvus Pharmaceuticals, Inc.
CRVS
X4 Pharmaceuticals, Inc.
XFOR
PDS Biotechnology Corporation
PDSB
Leap Therapeutics, Inc.
LPTX
Aileron Therapeutics, Inc.
ALRN
Pieris Pharmaceuticals, Inc.
PIRS
Artelo Biosciences, Inc.
ARTL
Histogen Inc.
HSTO
ETF Exposure (12)
iShares Micro-Cap ETF
IWC
0.00806%
Dimensional U.S. Core Equity 2 ETF
DFAC
1.727e-5%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%